Androgenetic Alopecia (AGA), also known as male or female pattern baldness, is a common form of hair loss characterized by a progressive thinning of hair in a specific pattern. In men, it typically starts with a receding hairline and balding at the crown. Women often experience a widening of the part and overall thinning of hair on the scalp.

 

AGA is primarily driven by genetic and hormonal factors. It's believed to be influenced by androgens, specifically dihydrotestosterone (DHT), which can shrink hair follicles, shorten the growth phase of hair, and result in finer, shorter, and less pigmented hair over time.

 

The diagnosis of AGA involves a medical history, physical examination, and sometimes additional tests like a scalp biopsy or blood tests to rule out other underlying conditions.

 

Treatment for AGA includes topical minoxidil (Rogaine), topical compounded prescription strength minoxidil combined with a topical DHT (dihydrotestosterone) blocker, oral DHT blockers (spironolactone, finasteride or dutasteride), oral low-dose minoxidil, and/or platelet-rich fibrinogen (PRF) therapy with microneedling and hair transplant surgery.

 

AGA is a chronic condition that requires ongoing management to maintain results. Early intervention can help slow down hair loss and improve the overall appearance of the hair.